Bing

SEARCH HISTORY

Healthcare stocks declined 0.5% on Wall Street on Monday. More broadly, the Dow Jones Industrial Average fell 1.8%, the Nasdaq was down 1.5% and the S&P 500 fell 1.8%. Some of the biggest gainers among healthcare stocks include …
Investor Place · 1/6/2015
The past year hasn't been the kindest to NPS Pharmaceuticals' (NASDAQ: NPSP.DL ) shareholders, with the stock vastly underperforming the broader market and its peers. Yet, take off your short-term blinders and examine NPS Pharmaceuticals' …
The Motley Fool · BySean Williams · 10/7/2014
NEW YORK (TheStreet) -- NPS Pharmaceuticals (NPSP) shares are up 8.2% to $45.36 on heavy volume in early market trading today after the company agreed to be bought by Britain's Shire plc (SHPG) yesterday for $5.2 billion. The purchase price …
The Street · 1/12/2015
More from Bing News
The most recent short interest data has been released by the NASDAQ for the 12/31/2014 settlement date, which shows a 1,345,476 share decrease in total total short interest for NPS Pharmaceuticals NPS Pharmaceuticals Inc. (NASD: NPSP), to 7,938 …
Forbes · 1/13/2015
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day. This reverses the downtrend for the company since May 5, as the stock is now down nearly 4%. In the last 30 days, the company witnessed three …
Yahoo Finance · 5/12/2014
as there has been some decidedly negative earnings estimate revisions in NPS Pharmaceuticals' stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of NPSP's prospects for the near term.
NASDAQ · 1/7/2015
as a result of an increase in operating costs following its acquisition of NPS Pharmaceuticals and investments in its pipeline. The Dublin-based drug company's interim results fell short of analyst expectations, and the stock is trading down 2.6% at 5,325 ...
4 Traders · 7/23/2015
as there has been some decidedly negative earnings estimate revisions in NPS Pharmaceuticals' stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of NPSP's prospects for the near term.
Benzinga · 1/7/2015
as a result of an increase in operating costs following its acquisition of NPS Pharmaceuticals and investments in its pipeline. The Dublin-based drug company's interim results fell short of analyst expectations, and the stock is trading down 2.6% at 5,325 ...
Morningstar · 7/23/2015
Acquisitions and deals continue to be in focus with yet another pharma company announcing its intention to acquire a biotech company. Meanwhile, interest in the immuno-oncology area shows no signs of slowing down with another deal being announced.
ZACKS · 1/14/2015